Wave Life Sciences Q2 2025 net loss $50.5M; cash $208.5M; key trial data on track

Wave Life Sciences Ltd.

2025-Q2 EPS reported -$0.60 revenue$17,874,000

Cash $208.5M as of June 30, 2025, down from $302.1M at Dec 31, 2024; runway into 2027.
Revenue $8.7M in Q2 2025 vs $19.7M YoY; net loss $50.5M vs $32.9M YoY.
WVE-006 AATD: multidose complete in 200mg cohort; 200mg data in 3Q 2025, 400mg data fall 2025.
WVE-007 obesity: expanded Cohort 2 (240mg) to 32; data from Cohorts 1 and 2 expected 4Q 2025.
Appointed Christopher Wright, MD, PhD, as Chief Medical Officer in May 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.